Search

Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.

• FAQ
• Written

These are some of the most commonly asked questions about volunteering for our charity.

You may have heard that a cell-based treatment approach (sometimes referred to as a “stem cell treatment”), developed by a company called ReNeuron, is being tested in a clinical trial at Oxford Eye Hospital and other centres in the US and Europe.

• News
• Retinitis pigmentosa

Fancy fundraising for Retina UK? Here’s a few pointers to help get you started.

Organising your own fundraising is great fun and a brilliant way to involve your friends, family and local community.

Leber Congenital Amaurosis (LCA) is a rare genetic eye disease that appears at birth or in the first few months of life.

The cost-of-living crisis is having a major impact on the lives of blind and partially sighted people. Many people are becoming increasingly concerned about how they will make ends meet. Sight Loss Charities have come together as between us we can offer help and support.

• News

Genetic testing, usually via a blood sample, is used to try and identify which gene contains the fault that is causing an individual’s sight loss.